In this month's newsletter, read up on our partnership with WakeMed to launch a robotic program and other news from Corindus.
Not rendering correctly? View this email as a web page here.
Corindus Announces Partnership with WakeMed Health & Hospitals to Launch Robotic Program
We recently announced that WakeMed Health & Hospitals will partner with Corindus to develop a national center of excellence to advance patient care and clinical robotics research and to train interventional cardiologists on robotic-assisted PCI using the CorPath GRX System. "I am proud to be part of a health system that represents the best training, the latest technologies and the highest commitment to patient care, safety and innovation," said Frances O. Wood, M.D., FACC, interventional cardiologist and co-director of Structural Heart at WakeMed Heart Center.
Corindus Vascular Robotics Announces Private Placement for $45 Million
We are pleased to announce the closing of a private placement for $45 million that involved a syndicate of top tier healthcare investors. New investors include Boston Scientific Corporation [NYSE: BSX], BioStar Ventures, Consonance Capital, and Hudson Executive Capital, LP. Existing investors, HealthCor Partners Management and Royal Philips [NYSE: PHG, AEX: PHIA] also participated. “The additional capital will allow us to continue the momentum created by strong interest in the recent launch of our next-generation CorPath GRX System and our expansion into Japan with an exclusive distribution agreement with MC Healthcare, Inc., a subsidiary of Mitsubishi Corporation,” said Mark Toland, President and Chief Executive Officer of Corindus.
Suspended Lead Curtain, Robotic PCI, Offer Significant Head Protection from Radiation during PCI
TCTMD recently ran an article highlighting a study performed at Spectrum Health in Grand Rapids, MI on the impact of multiple radiation protection devices on exposure levels of cath lab staff. The study found that a suspended lead curtain reduced cranial radiation exposure by 97% however, when compared with the lead curtain, operators who performed PCI with a robotic interventional system further reduced the risk of cranial radiation exposure by an additional 80%. The study’s lead investigator noted that over the course of a career, the difference in radiation exposure between the suspended lead suit and robotic system would be significant, particularly as physicians take on more complex PCI cases.
ORSIF: Health Impacts of Radiation Exposure during PCI
Concern regarding the health hazards associated with interventional fluoroscopy is growing, as evidence of the damaging effects of chronic exposure to ionizing radiation builds. More than 17 million fluoroscopy-guided interventional procedures take place each year. In an article published in Cath Lab Digest, Michael Seymour, MS, MPH, CIH, and Director of Advocacy Programs for ORSIF, discusses the increase in interventional cardiology procedures that rely on fluoroscopy and describes the research on the health effects, including cancer, cataracts, cognitive function, and reproductive effects. Musculoskeletal injuries associated with the use of heavy personal protective equipment (PPE), as well as other radiation-protection methods and their limitations, are also discussed.
CorPath 200 System is intended for use in the remote delivery and manipulation of coronary guidewires and balloon/stent catheters during PCI procedures
CorPath 200 System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters during percutaneous vascular interventional procedures.
The CorPath GRX is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
Caution: Federal law restricts this device to sale by or on the order of a physician.
Copyright Corindus, Inc. 309 Waverley Oaks Road, Suite 105, Waltham, MA 02452, US Corporate Office: 508-653-3335 | Sales & Customer Service: 800-605-9635 | Fax: 508-232-6000